Freezing threatens mRNA delivery, but Tris buffer helps nanoparticles retain their potency

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-25 • Permanent link

Frosty temperatures have brought a new challenge to the mRNA delivery process, as researchers at The University of Texas at Austin and pharmaceutical company Eli Lilly and Company have discovered that freezing conditions can compromise the potency of nanoparticles. The lipid nanoparticles, used to deliver genetic material, are sensitive to temperature fluctuations, which can affect their stability and efficacy. According to a recent study, the nanoparticles' ability to retain their potency was reduced by 25% when stored at temperatures below 4°C for extended periods.

Rising concerns over the impact on investors and consumers have sparked a flurry of interest in the scientific community. As mRNA-based treatments continue to gain traction in the fight against diseases, the stability of these nanoparticles is crucial. A delay in delivery can result in reduced treatment efficacy, leading to increased healthcare costs and a heavier burden on patients. With the potential for widespread adoption, the stability of mRNA nanoparticles is a critical factor in ensuring their successful implementation.

Industry experts point to the challenges posed by mRNA delivery as a reminder of the complexities involved in developing novel biotechnology solutions. The lipid nanoparticles, while promising, are still in the early stages of development, and their stability is just one of many factors that must be carefully considered. By studying the effects of temperature fluctuations, researchers can refine their delivery methods and improve the overall efficacy of mRNA-based treatments. This research has the potential to pave the way for more effective treatments, but it also highlights the need for continued investment in biotechnology research.

As the scientific community continues to explore the potential of mRNA delivery, investors are taking notice. With several major pharmaceutical companies already investing heavily in mRNA-based research, the market is poised for significant growth. However, the challenges posed by temperature fluctuations remain a significant risk, and investors will be watching closely as researchers continue to refine their delivery methods. In the coming months, investors will be eager to see updates on the development of mRNA-based treatments and the impact of these challenges on the broader biotechnology landscape.